Regeneron Pharmaceuticals, Inc.

Ergang Shi

Tammy T Huang

Ashique Rafique

Sean Stevens

Nicholas J Papadopoulos

Joel H Martin

Jeanette L Fairhurst

Kevin J Pobursky

Joan A Windsor

Warren R Mikulka

Marcela Torres

Raymond W Leidich

Diana M Ahrens

Robert Babb

Andrew J Murphy

Lynn Macdonald

Gang Chen

Wen-Yi Lee

David Suh

Glen Farr

Disclosed are methods for obtaining cells that express antibodies that bind transmembrane proteins, methods for generating antibodies from such cells, antibodies to transmembrane proteins and fragments thereof, and nucleic acids encoding the antibodies. More particularly, the disclosure relates to methods for obtaining antibody-producing cells that express an antibody that binds to a transmembrane protein based on the use of lipid bilayer-membrane scaffold protein complexes to present transmembrane protein antigens to cells.

Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same

Methods for making, identifying, isolating and/or making binding proteins that contain an immunoglobulin light chain variable domain, including a somatically hypermutated light chain variable domain, fused with a heavy chain constant region, are provided. Exemplary binding proteins specific to small molecules are also provided.

Vantigen binding proteins exhibiting distinct binding characteristics

An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R&#x3b1;) with an affinity constant (K) of less than 200 pM, as measured by surface plasmon resonance, is provided.

High affinity human antibodies to human IL-4 receptor

The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.

An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4R&#x3b1;) with an affinity constant (K) of less than 200 pM, as measured by surface plasmon resonance.

Growing community of inventors

Ossining, NY, United States of America

Ergang Shi